FindTrial
Sign In

adjuvant immunotherapy

DRUG5 trials

Sponsors

RenJi Hospital, Sun Yat-sen University, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Fudan University

Conditions

De-escaltion TherapyEsophageal Squamous Cell Carcinoma (ESCC)Muscle Invasive Upper Tract Urothelial CarcinomaNasopharyngeal CarcinomaResectable Stage II-IIIa NSCLCSquamous Cell Carcinoma of the Head and Neck

Phase 3

Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma
RecruitingNCT05877872
Sun Yat-sen UniversityDe-escaltion Therapy, Nasopharyngeal Carcinoma
Start: 2023-05-20End: 2029-03-30Target: 424Updated: 2023-05-26
De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Not yet recruitingNCT07320690
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversitySquamous Cell Carcinoma of the Head and Neck
Start: 2026-01-01End: 2031-07-01Target: 356Updated: 2026-01-06
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
Not yet recruitingNCT07554846
Fudan UniversityResectable Stage II-IIIa NSCLC
Start: 2026-05-01End: 2032-05-01Target: 759Updated: 2026-04-28

Unknown Phase

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
RecruitingNCT05595408
RenJi HospitalMuscle Invasive Upper Tract Urothelial Carcinoma
Start: 2022-02-01End: 2026-12-31Target: 84Updated: 2025-12-09
NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC
Active, not recruitingNCT06762158
RenJi HospitalEsophageal Squamous Cell Carcinoma (ESCC)
Start: 2024-10-30End: 2029-12-01Target: 50Updated: 2025-01-07